FDA is planning to issue several additional guidances on biosimilars in the “near future,” Sally Howard, Deputy Commissioner for Policy, Planning, Legislation And Analysis, said. But that policy work is not impacting the agency’s review of pending applications.
In fact, the user fee deadlines for the two biosimilar applications have been publically announced seem to be driving the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?